- Conditions
- Hypogonadism, Male
- Interventions
- LPCN 1021
- Drug
- Lead sponsor
- Lipocine Inc.
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 43
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Opioid Use, Pain, Hypogonadism, Male
- Interventions
- Testosterone Undecanoate 250 MG/ML, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Cypionate Injection 200 mg/mL
- Drug
- Lead sponsor
- Azurity Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 3 more
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Cypionate 200 Mg/ML, Intranasal Testosterone
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hypogonadism, Kallmann Syndrome
- Interventions
- Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH)
- Procedure · Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypogonadism, Male, Cancer, Fatigue
- Interventions
- testosterone 1.62% gel, placebo gel
- Drug · Other
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 55 Years and older · Male only
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Boston, Massachusetts • Seattle, Washington
- Conditions
- Hypogonadism, Male
- Interventions
- Clomiphene
- Drug
- Lead sponsor
- Phoenix VA Health Care System
- Federal
- Eligibility
- 30 Years to 70 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Hypogonadism, Hypogonadism, Male, Gonadal Disorders, Endocrine System Diseases, Testosterone Deficiency
- Interventions
- TSX-011
- Drug
- Lead sponsor
- TesoRx Pharma, LLC
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Adult Male Hypogonadism
- Interventions
- Testosterone Gel (FE 999093)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Newport Beach, California • San Diego, California + 13 more
- Conditions
- Hypogonadism, Male, Kidney Disease, Chronic
- Interventions
- Jatenzo Pill
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypogonadism
- Interventions
- Testosterone enanthate auto-injector
- Combination Product
- Lead sponsor
- Antares Pharma Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New York, New York • Columbus, Ohio
- Conditions
- Male Hypogonadism
- Interventions
- Oral testosterone undecanoate, topical testosterone gel
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
- Conditions
- Male Hypogonadism
- Interventions
- Oral testosterone undecanoate
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more
- Conditions
- Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications
- Interventions
- Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
- Diagnostic Test
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Male Hypogonadism
- Interventions
- testosterone gel 2%
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
- Conditions
- Hypogonadism, Malignant Testicular Germ Cell Tumor
- Interventions
- 7 Tesla Magnetic Resonance Imaging, Biospecimen Collection, Cognitive Assessment
- Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Hypogonadism, Male
- Interventions
- SOV2012-F1
- Drug
- Lead sponsor
- Marius Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Aventura, Florida + 16 more
- Conditions
- Hypogonadism
- Interventions
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 68 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Antonio, Texas
- Conditions
- Testosterone Deficiency, Hypogonadism, Male
- Interventions
- Testosterone
- Drug
- Lead sponsor
- Men's Health Boston
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Hypogonadism, Male
- Interventions
- Natesto
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Male Hypogonadism
- Interventions
- Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel)
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
- Conditions
- Hypogonadism, Male, Fatigue Syndrome, Chronic
- Interventions
- Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo
- Drug · Other
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 54 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Erectile Dysfunction, Hypogonadism, Male, Endothelial Dysfunction
- Interventions
- Daily low-dose PDE5 inhibitor therapy, Testosterone therapy as per clinical guidelines.
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Prostate Cancer, Hypogonadism, Male
- Interventions
- Testosterone cypionate
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Miami, Florida